Literature DB >> 34598278

Persistent Coronavirus Disease 2019 (COVID-19) in an Immunocompromised Host Treated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Monoclonal Antibodies.

Benoit Bailly1,2, Helene Péré3, David Veyer3,4, Ana Berceanu5, Etienne Daguindau5, Pauline Roux6, Olivier Hermine7, Xavier de Lamballerie8, Paul Bastard9,10,11, Karine Lacombe12, Brigitte Autran13,14, Fanny Angelot Delettre15,16, Jean Laurent Casanova10,11,17,18, Sandrine Imbeaud3, Anne Laure Clairet19, Marie Kroemer20,21, Laurie Spehner20,21, Nicolas Robillard22, Julien Puech22, Solène Marty-Quinternet23, Quentin Lepiller23, Catherine Chirouze1,24, Kevin Bouiller1,24.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 34598278      PMCID： PMC8522390          DOI： 10.1093/cid/ciab868

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  3 in total

Review 1.  Identifying Markers of Emerging SARS-CoV-2 Variants in Patients With Secondary Immunodeficiency.

Authors:  Nathan M Markarian; Gaël Galli; Dhanesh Patel; Mark Hemmings; Priya Nagpal; Albert M Berghuis; Levon Abrahamyan; Silvia M Vidal
Journal:  Front Microbiol       Date:  2022-07-01       Impact factor: 6.064

2.  Severe relapse of SARS-CoV-2 infection in a kidney transplant recipient with negative nasopharyngeal SARS-CoV-2 RT-PCR after rituximab.

Authors:  Antoine Morel; Sandrine Imbeaud; Anne Scemla; Hélène Péré; Jacques Fourgeaud; Lucile Amrouche; Nicolas Robillard; Delphine Planas; Julien Puech; Sylvie Simon; Fanny Lanternier; Laurent Bélec; Julien Zuber; Olivier Schwartz; Dany Anglicheau; Nathalie Chavarot; David Veyer
Journal:  Am J Transplant       Date:  2022-03-01       Impact factor: 9.369

3.  Persistently positive PCR SARS-CoV-2 at low cycle threshold in an immunosuppressed patient.

Authors:  Rosa-María Martín-Díaz; Jon Cabrejas-Ugartondo; Mar Iglesias-López; Beatriz Chulvi-Calvo; Desirée Vélez-Rodriguez
Journal:  Braz J Infect Dis       Date:  2022-08-22       Impact factor: 3.257
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.